Arcellx (ACLX) Change in Accured Expenses (2021 - 2025)
Arcellx's quarterly Change in Accured Expenses came in at $958000.0 in Q4 2025, down 97.51% year-on-year from $38.5 million in Q4 2024, and down 45.35% quarter-over-quarter from $1.8 million in Q3 2025.
Arcellx has reported Change in Accured Expenses for 5 years, with the latest figure at $958000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 97.51% year-over-year to $958000.0; the trailing twelve-month figure through Dec 2025 stood at $2.7 million (down 93.66% YoY), and the FY2025 full-year result was $2.7 million, down 93.66% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at $958000.0, down from $1.8 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $38.5 million in Q4 2024, with the low at -$23.2 million in Q3 2024.
- Average Change in Accured Expenses over 5 years is $2.9 million, with a median of $1.1 million recorded in 2021.
- Year-over-year, Change in Accured Expenses plunged 2165.78% in 2023 and jumped 1946.36% in 2024.
- Tracing ACLX's Change in Accured Expenses over 5 years: stood at $1.3 million in 2021, then tumbled by 248.74% to -$1.9 million in 2022, then jumped by 483.32% to $7.2 million in 2023, then jumped by 431.63% to $38.5 million in 2024, then slumped by 97.51% to $958000.0 in 2025.
- The last three Change in Accured Expenses figures came in at $958000.0 (Q4 2025), $1.8 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 958,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 958,000.00 |
| Dec 31, 2025 | 958,000.00 |
| Sep 30, 2025 | 1.75 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Mar 31, 2025 | 2.24 Mn |
| Mar 31, 2025 | 2.24 Mn |
| Dec 31, 2024 | 38.50 Mn |
| Dec 31, 2024 | 38.50 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | 17.68 Mn |
| Mar 31, 2024 | 17.68 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Sep 30, 2023 | 2.15 Mn |
| Sep 30, 2023 | 2.15 Mn |
| Jun 30, 2023 | 440,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Mar 31, 2023 | -4.24 Mn |
| Mar 31, 2023 | -4.24 Mn |
| Dec 31, 2022 | -1.89 Mn |
| Dec 31, 2022 | -1.89 Mn |
| Sep 30, 2022 | -4.17 Mn |
| Sep 30, 2022 | -4.17 Mn |
| Jun 30, 2022 | 5.85 Mn |
| Jun 30, 2022 | 5.85 Mn |
| Mar 31, 2022 | -187,000.00 |
| Mar 31, 2022 | -187,000.00 |
| Dec 31, 2021 | 1.27 Mn |
| Dec 31, 2021 | 1.27 Mn |
| Sep 30, 2021 | 5.49 Mn |
| Sep 30, 2021 | 5.49 Mn |
| Jun 30, 2021 | 679,000.00 |
| Jun 30, 2021 | 679,000.00 |
| Mar 31, 2021 | 321,000.00 |
| Mar 31, 2021 | 321,000.00 |